Amneal Pharmaceuticals, Inc.(AMRX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,005 of 2,961 stocksTOP 50%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in AMRX
Events flagged as statistical outliers against AMRX's own multi-year baseline — not fixed dollar thresholds.
- Score shock2026-08-06
AMRX quality score dropped 9 points (59→50) on a new filing
View source filing →
AMRX Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Amneal Pharmaceuticals, Inc. (AMRX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AMRX at 58.5/100 on a 32-signal composite quality model, placing it at rank #1,005 of 2,961 stocks — the top half of the AI-ranked universe. Areas of concern include institutional flow (36.6) and free cash flow (39.0), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), Amneal Pharmaceuticals, Inc. reports quarterly revenue of $796.2M, net income of $57.7M, an operating margin of 16.3%. Top institutional holders of AMRX by reported 13-F value include BlackRock, TPG GP A, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. AMRX trades on the Nasdaq exchange and files with the SEC under CIK 1723128. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AMRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Amneal Pharmaceuticals, Inc. directly from SEC EDGAR. Amneal Pharmaceuticals, Inc.'s 13F Pro composite quality score has ranged between 36 and 64 since 2021, currently 58.5 — a stable long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$796.2M
Net Income
Q2 2026
$57.7M
Free Cash Flow
Q2 2026
$-51.9M
Operating Margin
Q2 2026
16.3%
ROIC
Q2 2026
19.9%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+8.0% YoYNet Income
+161.6% YoYOperating Income
+58.1% YoYEPS (Diluted)
+157.9% YoYTotal Assets
+5.1% YoYTotal Debt
-1.2% YoYOp. Cash Flow
+15.2% YoYFree Cash Flow
+11.0% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $3.02B +8.0% | $2.79B +16.7% | $2.39B +8.2% | $2.21B +5.7% | $2.09B +5.1% | $1.99B |
| Net Income | $72.1M +161.6% | $-116.9M -39.2% | $-84.0M +69.0% | $-270.6M -2155.6% | $13.2M -80.6% | $67.8M |
| Operating Income | $394.1M +58.1% | $249.3M +22.0% | $204.4M +315.3% | $-94.9M -162.2% | $152.7M +67.5% | $91.2M |
| EPS (Diluted) | $0.22 +157.9% | $-0.38 +20.8% | $-0.48 +44.2% | $-0.86 -1328.6% | $0.07 -88.5% | $0.61 |
| Total Assets | $3.68B +5.1% | $3.50B +0.8% | $3.47B -8.6% | $3.80B -3.6% | $3.94B -1.7% | $4.01B |
| Total Debt | $2.58B -1.2% | $2.61B +6.4% | $2.45B -7.5% | $2.65B -3.3% | $2.74B -4.4% | $2.87B |
| Operating Cash Flow | $340.0M +15.2% | $295.1M -14.6% | $345.6M +430.8% | $65.1M -73.1% | $241.8M -36.2% | $379.0M |
| Free Cash Flow | $269.9M +11.0% | $243.2M -19.6% | $302.4M +1517.5% | $18.7M -90.4% | $194.1M -39.8% | $322.6M |
Get alerted when AMRX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Amneal Pharmaceuticals, Inc. including:
Top Institutional Holders of AMRX
BlackRock, Inc.
$459.8M26,562,093 shTPG GP A, LLC
$213.4M12,328,767 shVANGUARD PORTFOLIO MANAGEMENT LLC
$210.1M12,137,727 shRubric Capital Management LP
$176.0M10,168,660 shVANGUARD CAPITAL MANAGEMENT LLC
$133.5M7,710,126 shSTATE STREET CORP
$127.3M7,356,977 shDIMENSIONAL FUND ADVISORS LP
$100.3M5,794,263 shGEODE CAPITAL MANAGEMENT, LLC
$89.0M5,139,449 shMORGAN STANLEY
$71.1M4,110,028 shNeuberger Berman Group LLC
$67.3M3,887,179 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $459.8M | 26,562,093 |
| TPG GP A, LLC | $213.4M | 12,328,767 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $210.1M | 12,137,727 |
| Rubric Capital Management LP | $176.0M | 10,168,660 |
| VANGUARD CAPITAL MANAGEMENT LLC | $133.5M | 7,710,126 |
| STATE STREET CORP | $127.3M | 7,356,977 |
| DIMENSIONAL FUND ADVISORS LP | $100.3M | 5,794,263 |
| GEODE CAPITAL MANAGEMENT, LLC | $89.0M | 5,139,449 |
| MORGAN STANLEY | $71.1M | 4,110,028 |
| Neuberger Berman Group LLC | $67.3M | 3,887,179 |
Companies Similar to AMRX
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Envista Holdings Corp
ANI PHARMACEUTICALS INC
Pediatrix Medical Group, Inc.
Aveanna Healthcare Holdings, Inc.
Integer Holdings Corp
BrightSpring Health Services, Inc.
BRIGHT HORIZONS FAMILY SOLUTIONS INC.
Option Care Health, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put AMRX on your watchlist
Track score changes the day Amneal Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is AMRX a good stock to buy?
13F Pro's AI-powered analysis of Amneal Pharmaceuticals, Inc. (AMRX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AMRX are available on the AMRX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. AMRX is classified as a mid company.
Which hedge funds own AMRX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AMRX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Amneal Pharmaceuticals, Inc.'s investment landscape.